Anticoagulant for primary percutaneous coronary intervention – the last dance for unfractionated heparin?  by Silvain, Johanne & Montalescot, Gilles
Archives of Cardiovascular Disease (2012) 105, 259—261
Available  online  at
www.sciencedirect.com
SCIENTIFIC EDITORIAL
Anticoagulant  for  primary  percutaneous  coronary
intervention  —  the  last  dance  for  unfractionated
heparin?
Anticoagulation  de  l’angioplastie  primaire  —  dernière  danse  pour  l’héparine  ?
Johanne  Silvain1, Gilles  Montalescot ∗,1
Inserm  UMRS  937,  université  Paris-6,  institut  de  cardiologie,  bureau  2-236,  centre  hospitalier
universitaire  Pitié-Salpêtrière  (AP—HP),  47,  boulevard  de  l’Hôpital,  75013  Paris,  France
Received 9  March  2012;  accepted  11  March  2012









Infarctus  myocarde  ;
Anticoagulation  ;
Héparine  ;
Héparine  de  bas  poids
moleculaire  ;
Bivalirudine
Rates  of  short-  and  long-term  mortality  after  an  acute  coronary  syndrome  (ACS)  have
been  reduced  dramatically  through  advances  in  percutaneous  coronary  intervention  (PCI)
techniques  and  the  availability  of  new  antithrombotic  agents.  This  is  particularly  true  for
patients  with  ST-elevation  myocardial  infarction  (STEMI)  treated  with  primary  PCI.  On  the
antiplatelet  side,  we  have,  besides  clopidogrel,  two  new  P2Y12 inhibitors  —  prasugrel  and
ticagrelor  —  for  which  data  and  subset  analyses  have  allowed  a  better  understanding  of
which  patients  with  an  ACS  would  truly  beneﬁt  from  these  drugs.  On  the  anticoagulant
side,  besides  unfractionated  heparin  (UFH),  we  have  three  newer  anticoagulants  that  can
be  used  in  ACS:  enoxaparin,  fondaparinux  and  bivalirudin.  In  this  competitive  ﬁeld,  the
past  decade  has  provided  a  large  ﬂow  of  evidence-based  information  in  terms  of  the  safety
and  efﬁcacy  of  these  antithrombotic  agents.  This  information  needs  to  be  implemented
both  in  guidelines  and  in  our  daily  clinical  practice.  As  always,  there  is  no  simple  rule
or  conclusion;  rather,  different  options  exist  according  to  current  practice  and  our  own
personal  environment  and  experiences.
The  efﬁcacy  of  anticoagulation  therapy  is  evaluated  on  the  basis  of  ischaemic
complications  of  ACS  and  sometimes  the  outcome  of  PCI  itself,  both  of  which  have  a
real  impact  on  short-  and  long-term  mortality.  The  ﬁrst  goal  of  anticoagulation  therapy
during  primary  PCI  of  STEMI  is  therefore  to  avoid  or  control  at  all  times  the  development
of  thrombus  and  in  doing  so  obtain  or  maintain  blood  ﬂow  through  the  coronary  circulation
and  protect  the  myocardium  from  harmful  damage  related  to  ischaemia  and  necrosis.  If  the
drug  efﬁcacy  translates  into  a  mortality  reduction,  there  is  a  good  chance  of  recognition
and  acceptation  of  the  new  treatment  by  practising  physicians.
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Safety  is  also  a  major  issue  of  anticoagulation  ther-
py:  all  of  these  drugs  increase  the  risk  of  instrumental
r  spontaneous  bleeding,  leading  to  more  transfusions  and
ubsequently  higher  morbidity  and  mortality  [1].  Lowering
nstrumental  or  procedure-related  bleeding  is  very  impor-
ant;  when  interventional  cardiologists  are  not  sufﬁciently
killed  to  perform  PCI  through  the  radial  approach,  this
educed  bleeding  risk  can  be  achieved  with  the  use  of  a  more
table  anticoagulant  and  a  lower  level  of  anticoagulation.
The  latest  data  on  the  efﬁcacy  (ischaemic  and  mor-
ality  endpoints)  and  safety  (major  bleeding  endpoint)  of
he  three  newest  anticoagulants  —  enoxaparin,  fondaparinux
nd  bivalirudin  —  tested  in  primary  PCI  for  patients  with
TEMI  are  provided  in  Table  1.
In  the  Harmonizing  Outcomes  with  Revascularization  and
tents  (HORIZONS)  trial  [2],  bivalirudin  did  not  reduce  the
ate  of  the  ischaemic  endpoint  compared  with  UFH  (rela-
ive  risk  [RR]  0.99,  95%  conﬁdence  interval  [CI]  0.76—1.30);
he  trial  involved  3602  patients  with  STEMI  treated  by  pri-
ary  PCI  and  had  sufﬁcient  power  to  address  this  question.
owever,  the  main  result  of  the  trial  was  a  40%  reduc-
ion  in  the  safety  endpoint  (RR  0.60,  95%  CI  0.46—0.77),
orresponding  to  both  procedure-related  and  spontaneous
leedings;  the  result  was  of  such  a  magnitude  that  mortality
as  also  reduced  signiﬁcantly  (RR  0.66,  95%  CI  0.44—1.00).
his  explanation  of  the  mortality  reduction  is  consistent
ith  other  trials  that  also  reduced  procedure-related  major
leeding  and  mortality,  with  a  radial  approach  rather  than  a
emoral  approach  [3].  In  the  Radial  Versus  Femoral  Investi-
ation  (RIFLE)  trial,  radial  access  reduced  procedure-related
ajor  bleedings  by  47%  and  subsequently  mortality  by
7%,  without  any  impact  on  ischaemic  endpoints  [3].  These
esults  highlight  that  safety  is  a  serious  issue  and  that
mprovement  in  safety  can  have  a  direct  impact  on  mor-
ality,  especially  when  considering  PCI  performed  via  the
emoral  approach.
Fondaparinux  was  compared  with  UFH  in  the  Optimal
ntiplatelet  Strategy  for  Interventions  6  (OASIS)  trial  [4]  —a
arge  trial  of  12,092  STEMI  patients.  However,  only  3789
atients  were  treated  by  primary  PCI,  and  the  results  regard-
ng  this  indication  were  in  opposition  to  the  group  of  patients
reated  medically  or  by  ﬁbrinolysis,  with  a  signiﬁcant  P
alue  for  interaction  (P  =  0.04).  Indeed,  at  30  days  the  clas-
ic  ischaemic  endpoint  of  death  or  myocardial  infarction
as  increased  by  20%  (RR  1.20,  95%  0.91—1.57),  also  with
 trend  towards  a  higher  rate  of  severe  bleeding,  which  was
ncreased  by  18%  (RR  1.18,  95%  CI  0.63—2.22);  this  led  to
 non-signiﬁcant  but  worrying  increase  of  16%  in  all-cause
ortality  (RR  1.16,  95%  CI  0.85—1.58).  Therefore,  with  such
esults,  fondaparinux  cannot  be  recommended  in  primary
CI  for  STEMI  patients.
Enoxaparin,  when  compared  with  UFH  in  the  Acute  STEMI
reated  with  primary  angioplasty  and  intravenous  enoxa-
arin  Or  UFH  to  Lower  ischemic  and  bleeding  events  at
hort-  and  Long-term  follow-up  (ATOLL)  trial  [5],  reduced
he  classic  ischaemic  endpoint  of  death,  recurrent  myocar-
ial  infarction/ACS  or  urgent  revascularization  by  41%  (RR
.59,  95%  CI  0.38—0.91),  with  even  a  trend  towards  a  40%
ortality  reduction  (RR  0.60,  95%  CI  0.33—1.07),  which  wasigniﬁcant  when  considering  the  combination  of  death  and
esuscitated  cardiac  arrest  (P  =  0.049).  The  rate  of  major
leeding  did  not  differ  between  the  two  arms  and  the
d
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ffect  on  mortality  appeared,  this  time,  to  be  in  opposi-
ion  to  bivalirudin,  driven  by  the  reduction  in  the  rate  of
schaemic  endpoints.  The  primary  endpoint  of  the  ATOLL
rial  combining  ischaemic,  bleeding  and  procedural  events
as  also  reduced,  although  the  P  value  fell  short  of  sta-
istical  signiﬁcance  (P  =  0.06).  The  expected  reduction  in
ajor  bleeding  with  enoxaparin  did  not  occur,  most  likely
ue  to  predominant  use  of  the  radial  access,  an  unusual  pre-
ominant  approach  in  international  trials  of  primary  PCI.
he  lack  of  power  for  hard  endpoints  in  the  comparison
etween  enoxaparin  and  UFH  in  the  ATOLL  trial  was  solved
y  the  publication  of  two  recent  meta-analyses  from  differ-
nt  research  groups.  The  ﬁrst  study  [6]  focused  on  primary
CI,  showing  that  low-molecular-weight  heparin  (in  most
ases  enoxaparin)  was  superior  in  reducing  mortality,  by  49%
RR  0.51,  95%  CI  0.41—0.64)  and  major  bleeding  by  32%  (RR
.68,  95%  CI  0.49—0.94)  when  regrouping  the  data  of  16,286
atients.  The  second  meta-analysis  [7]  pooled  more  than
0,000  patients  treated  with  enoxaparin  only,  and  extended
hese  results  to  all  types  of  PCI,  with  a  global  reduction
n  mortality  of  34%  (RR  0.66,  95%  CI  0.57—0.76)  indepen-
ently  of  the  clinical  presentation.  The  beneﬁt  was  driven
argely  by  the  effect  obtained  in  the  10,243  STEMI  patients
reated  with  primary  PCI,  with  a  reduction  in  mortality  of
8%  (RR  0.52,  95%  CI  0.42—0.64),  through  a  combined  effect
n  the  ischaemic  endpoints  (recurrent  myocardial  infarc-
ion  or  complication  of  myocardial  infarction  was  reduced
y  24%;  RR  0.76,  95%  CI  0.60—0.96)  and  bleeding  endpoints,
hich  were  reduced  by  28%  (RR  0.72,  95%  CI  0.56—0.93).
hese  meta-analyses  conﬁrm  and  reinforce  the  ATOLL  ﬁnd-
ngs,  with  an  improved  safety  and  efﬁcacy  globally  with
noxaparin  compared  with  UFH.
Taking  all  of  this  information  into  account,  what  should
e  use  for  the  anticoagulation  of  our  patients  in  primary
CI?  Should  we  prefer  a  reduction  in  the  risk  of  major  bleed-
ng,  translating  into  a  reduction  of  mortality,  or  should  we
se  drugs  that  decrease  the  risk  of  ischaemic  endpoints
and  bleeding  in  femoral  primary  PCI),  with  also  a  beneﬁt
n  mortality?  The  next  European  guidelines  should  update
he  levels  of  recommendation  for  anticoagulants  in  primary
CI.  The  level  of  evidence  for  UFH  in  the  current  guidelines
emains  poor  (level  C).  UFH  could  be  downgraded,  as  at  least
wo  other  options  look  superior  (bivalirudin  and  enoxaparin)
ith  a  direct  impact  on  mortality.
In  selecting  strategies,  bivalirudin  appears  to  be  a  valid
hoice  in  centres  using  both  a femoral  approach  and  glyco-
rotein  IIb/IIIa  inhibitors,  with  the  idea  of  reducing  bleeding
ith  a  glycoprotein  IIb/IIIa-inhibitor  —  sparing  strategy.  In
adial  centres,  this  strategy  is  less  attractive,  radial  access
eing  a  safety  net  for  the  use  of  glycoprotein  IIb/IIIa
nhibitors,  which  still  have  a  good  indication  in  primary  PCI,
specially  when  patients  present  early  and  need  a  transfer
8].  Whether  the  beneﬁt  of  bivalirudin  can  be  reproduced
ith  radial  primary  PCI  is  unknown,  but  is  currently  being
ested  in  the  randomized  international  Minimizing  Adverse
aemorrhagic  Events  by  TRansradial  Access  Site  and  Sys-
emic  Implementation  of  angioX  (MATRIX)  trial,  which  should
nclude  6200  STEMI  patients  (NCT01433627).  Enoxaparin  is
he  alternative  to  UFH,  with  some  major  advantages:  the
rug  is  widely  available  worldwide,  inexpensive,  well  known
y  all  cardiologists,  with  a  pharmacodynamic  proﬁle  per-
ectly  adapted  to  primary  PCI,  excellent  clinical  results  in
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Table  1  Main  results  trial  and  meta-analysis  of  anticoagulants  compared  to  UFH  in  primary  PCI  for  STEMI  patients.  The
ischaemic  endpoint  (hazard  ratio  and  95%  conﬁdence  interval)  was  the  main  ischaemic  endpoint  available  in  the  study
results  at  30  days.  It  was  the  combination  of  death,  recurrent  myocardial  infarction/acute  coronary  syndrome  or  urgent
revascularization  in  ATOLL;  the  combination  of  death,  recurrent  MI,  urgent  target  vessel  revascularization  and  stroke  in
HORIZONS;  and  the  combination  of  death  and  recurrent  MI  for  OASIS-6.  The  bleeding  endpoint  was  the  main  deﬁnition
used  for  major/severe  bleeding  in  each  trial  that  was  available.
Authors  Study  Anticoagulant  Patients
(n)
Ischaemic  Major  bleeding  All-cause  mortality
Silvain  et  al.  [7] Meta-analysis
(primary  PCI)
Enoxaparin 10,243 0.76a (0.60—0.96) 0.72a (0.56—0.93) 0.52a (0.42—0.64)
Montalescot
et  al.  [5]
ATOLL  Enoxaparin  910  0.59a (0.38—0.91)  0.92  (0.51—1.66)  0.60  (0.33—1.07)
Stone  et  al.  [2]  HORIZONS  Bivalirudin  3602  1.00  (0.75—1.32)  0.60a (0.46—0.77)  0.66a (0.44—1.00)
Yusuf  et  al.  [4]  OASIS  6
(primary  PCI)











primary  PCI  in  terms  of  efﬁcacy  and  safety,  and  can  be
used  with  or  without  glycoprotein  IIb/IIIa  inhibitors,  the
ischaemic  beneﬁt  remaining  consistent  regardless  of  the
arterial  access.
While  waiting  for  a  trial  comparing  enoxaparin  with
bivalirudin  in  primary  PCI,  the  main  conclusion  is  that  we
are  moving  away  from  UFH  in  this  procedure.
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